Cargando…
Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of S...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099796/ https://www.ncbi.nlm.nih.gov/pubmed/36444554 http://dx.doi.org/10.1002/cncr.34561 |
_version_ | 1785025132096389120 |
---|---|
author | Dudley, Isabelle M. Sunguc, Ceren Heymer, Emma J. Winter, David L. Teepen, Jop C. Belle, Fabiën N. Bárdi, Edit Bagnasco, Francesca Gudmundsdottir, Thorgerdur Skinner, Roderick Michel, Gisela Byrne, Julianne Øfstaas, Hilde Jankovic, Momcilo Mazić, Maja Česen Mader, Luzius Loonen, Jaqueline Garwicz, Stanislaw Wiebe, Thomas Alessi, Daniela Allodji, Rodrigue S. Haddy, Nadia Grabow, Desiree Kaatsch, Peter Kaiser, Melanie Maule, Milena M. Jakab, Zsuzsanna Gunnes, Maria Winther Terenziani, Monica Zaletel, Lorna Zadravec Kuehni, Claudia E. Haupt, Riccardo de Vathaire, Florent Kremer, Leontien C. Lähteenmäki, Päivi M. Winther, Jeanette F. Hjorth, Lars Hawkins, Michael M. Reulen, Raoul C. |
author_facet | Dudley, Isabelle M. Sunguc, Ceren Heymer, Emma J. Winter, David L. Teepen, Jop C. Belle, Fabiën N. Bárdi, Edit Bagnasco, Francesca Gudmundsdottir, Thorgerdur Skinner, Roderick Michel, Gisela Byrne, Julianne Øfstaas, Hilde Jankovic, Momcilo Mazić, Maja Česen Mader, Luzius Loonen, Jaqueline Garwicz, Stanislaw Wiebe, Thomas Alessi, Daniela Allodji, Rodrigue S. Haddy, Nadia Grabow, Desiree Kaatsch, Peter Kaiser, Melanie Maule, Milena M. Jakab, Zsuzsanna Gunnes, Maria Winther Terenziani, Monica Zaletel, Lorna Zadravec Kuehni, Claudia E. Haupt, Riccardo de Vathaire, Florent Kremer, Leontien C. Lähteenmäki, Päivi M. Winther, Jeanette F. Hjorth, Lars Hawkins, Michael M. Reulen, Raoul C. |
author_sort | Dudley, Isabelle M. |
collection | PubMed |
description | BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. METHODS: The Pan‐European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow‐Up Studies (PanCareSurFup) cohort includes 69,460 five‐year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. RESULTS: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). CONCLUSIONS: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy. |
format | Online Article Text |
id | pubmed-10099796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-100997962023-04-14 Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study Dudley, Isabelle M. Sunguc, Ceren Heymer, Emma J. Winter, David L. Teepen, Jop C. Belle, Fabiën N. Bárdi, Edit Bagnasco, Francesca Gudmundsdottir, Thorgerdur Skinner, Roderick Michel, Gisela Byrne, Julianne Øfstaas, Hilde Jankovic, Momcilo Mazić, Maja Česen Mader, Luzius Loonen, Jaqueline Garwicz, Stanislaw Wiebe, Thomas Alessi, Daniela Allodji, Rodrigue S. Haddy, Nadia Grabow, Desiree Kaatsch, Peter Kaiser, Melanie Maule, Milena M. Jakab, Zsuzsanna Gunnes, Maria Winther Terenziani, Monica Zaletel, Lorna Zadravec Kuehni, Claudia E. Haupt, Riccardo de Vathaire, Florent Kremer, Leontien C. Lähteenmäki, Päivi M. Winther, Jeanette F. Hjorth, Lars Hawkins, Michael M. Reulen, Raoul C. Cancer Original Articles BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. METHODS: The Pan‐European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow‐Up Studies (PanCareSurFup) cohort includes 69,460 five‐year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. RESULTS: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). CONCLUSIONS: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy. John Wiley and Sons Inc. 2022-11-29 2023-02-01 /pmc/articles/PMC10099796/ /pubmed/36444554 http://dx.doi.org/10.1002/cncr.34561 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Dudley, Isabelle M. Sunguc, Ceren Heymer, Emma J. Winter, David L. Teepen, Jop C. Belle, Fabiën N. Bárdi, Edit Bagnasco, Francesca Gudmundsdottir, Thorgerdur Skinner, Roderick Michel, Gisela Byrne, Julianne Øfstaas, Hilde Jankovic, Momcilo Mazić, Maja Česen Mader, Luzius Loonen, Jaqueline Garwicz, Stanislaw Wiebe, Thomas Alessi, Daniela Allodji, Rodrigue S. Haddy, Nadia Grabow, Desiree Kaatsch, Peter Kaiser, Melanie Maule, Milena M. Jakab, Zsuzsanna Gunnes, Maria Winther Terenziani, Monica Zaletel, Lorna Zadravec Kuehni, Claudia E. Haupt, Riccardo de Vathaire, Florent Kremer, Leontien C. Lähteenmäki, Päivi M. Winther, Jeanette F. Hjorth, Lars Hawkins, Michael M. Reulen, Raoul C. Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title | Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title_full | Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title_fullStr | Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title_full_unstemmed | Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title_short | Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study |
title_sort | risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in europe: the pancaresurfup study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099796/ https://www.ncbi.nlm.nih.gov/pubmed/36444554 http://dx.doi.org/10.1002/cncr.34561 |
work_keys_str_mv | AT dudleyisabellem riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT sungucceren riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT heymeremmaj riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT winterdavidl riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT teepenjopc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT bellefabienn riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT bardiedit riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT bagnascofrancesca riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT gudmundsdottirthorgerdur riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT skinnerroderick riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT michelgisela riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT byrnejulianne riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT øfstaashilde riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT jankovicmomcilo riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT mazicmajacesen riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT maderluzius riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT loonenjaqueline riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT garwiczstanislaw riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT wiebethomas riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT alessidaniela riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT allodjirodrigues riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT haddynadia riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT grabowdesiree riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT kaatschpeter riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT kaisermelanie riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT maulemilenam riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT jakabzsuzsanna riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT gunnesmariawinther riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT terenzianimonica riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT zaletellornazadravec riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT kuehniclaudiae riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT hauptriccardo riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT devathaireflorent riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT kremerleontienc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT lahteenmakipaivim riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT wintherjeanettef riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT hjorthlars riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT hawkinsmichaelm riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy AT reulenraoulc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy |